Back to List View Graph View

CD3+

CD3+ refers to cells that express the cluster of differentiation 3 (CD3) glycoprotein complex, a surface antigen expressed on the majority of T lymphocytes and a critical component of the T cell receptor (TCR) signaling machinery.

Where the papers sit

15 papers from the last 6 months study CD3+ directly · updated from PubMed 16 Nov 2026

  • Engineered CD3 T-Cell Engagers

    Engineered CD3 T-cell engagers are moving beyond conventional surface targets through FAP×CD3, TCR-mimic recognition of intracellular antigens and affinity or valency tuning. Preclinical work spans solid-tumor cytotoxicity, BCMA-directed B-cell depletion and activity at distant untreated tumor sites. DNA hypomethylating agents are being used to preserve T-cell stemness and strengthen responses. Broad target coverage, controlled activation and translation from preclinical models remain the central challenges.

    6 papers · 40%

  • Bispecific Therapy in Myeloma

    Teclistamab and talquetamab are extending T-cell redirection in relapsed or refractory multiple myeloma, including talquetamab–daratumumab combinations. Cytokine release syndrome, infections, B-cell effects and GPRC5D-related toxicities recur as the main management problems. Dexamethasone and structured adverse-event monitoring support treatment delivery. QSP modeling and pharmacovigilance point toward better dosing and safety mitigation, while durability and comparative benefit remain open.

    5 papers · 33.3%

  • T-Cell Engagers in B-Cell Malignancies

    CD3 bispecifics are moving B-cell malignancy treatment toward deep, measurable remissions, with epcoritamab MRD negativity and blinatumomab-based pretransplant therapy linking T-cell redirection to relapse control. Glofitamab and related agents are being evaluated across relapsed lymphoma and transplant settings. Peripheral CD4+ T-cell reserve may help predict response, while donor-lymphocyte redirection seeks stronger graft-versus-leukemia effects. Durability, immune competence and integration with BTK inhibition or allotransplant remain unresolved.

    4 papers · 26.7%

Papers

The 15 papers from the last 6 months that study CD3+ directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Engineered CD3 T-Cell Engagers (6)
  1. The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
  2. Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy. Science bulletin · 10 Sept 2026 PMID 42722595
  3. Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors. Proceedings of the National Academy of Sciences of the United States of America · 4 Sept 2026 PMID 42696537
  4. Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
  5. TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. Signal transduction and targeted therapy · 24 Jun 2026 PMID 42342658
  6. DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524
Bispecific Therapy in Myeloma (5)
  1. Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
  2. Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience. Hematology (Amsterdam, Netherlands) · 1 Sept 2026 PMID 42679119
  3. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. The New England journal of medicine · 15 Jun 2026 PMID 42294841
  4. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
  5. Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
T-Cell Engagers in B-Cell Malignancies (4)
  1. Peripheral CD4+ T-Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor-Associated Immune Modulation in B-Cell Lymphoma. Hematological oncology · 10 Oct 2026 PMID 42858312
  2. MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. Blood advances · 10 Jul 2026 PMID 42431612
  3. Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
  4. "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL. Blood advances · 20 May 2026 PMID 42160762

By study type

Clinical trials (5)
  1. Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience. Hematology (Amsterdam, Netherlands) · 1 Sept 2026 PMID 42679119
  2. MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. Blood advances · 10 Jul 2026 PMID 42431612
  3. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. The New England journal of medicine · 15 Jun 2026 PMID 42294841
  4. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
  5. Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
Observational studies and case reports (4)
  1. Peripheral CD4+ T-Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor-Associated Immune Modulation in B-Cell Lymphoma. Hematological oncology · 10 Oct 2026 PMID 42858312
  2. Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
  3. Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
  4. "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL. Blood advances · 20 May 2026 PMID 42160762
Preclinical: animal, cell and lab studies (6)
  1. The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
  2. Activation-optimized anti-CD3 valency control enables combinatorial discovery of multi-specific nanoantibodies for solid tumor immunotherapy. Science bulletin · 10 Sept 2026 PMID 42722595
  3. Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors. Proceedings of the National Academy of Sciences of the United States of America · 4 Sept 2026 PMID 42696537
  4. Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
  5. TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. Signal transduction and targeted therapy · 24 Jun 2026 PMID 42342658
  6. DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524